Dr. Ali Khaki on managing toxicities with enfortumab vedotin for bladder cancer

Ali Raza Khaki, MD, genitourinary specialist, clinical assistant professor, Medicine – Oncology, Stanford Medicine, discusses managing toxicities to ensure patients can continue to receive treatment with the antibody-drug conjugate enfortumab vedotin-ejfv (Padcev). Khaki shared this information with his colleagues at a recent clinical workshop.

Enfortumab vedotin is approved by the FDA for the treatment of patients with locally advanced or metastatic urothelial cancer who have previously received a PD-1/PD-L1 inhibitor and platinum-containing chemotherapy; or patients who are ineligible for cisplatin-containing chemotherapy and have previously received 1 or more prior lines of therapy.